|Bid||101.40 x 100|
|Ask||105.00 x 200|
|Day's Range||101.16 - 103.21|
|52 Week Range||79.62 - 137.88|
|PE Ratio (TTM)||-24.24|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||150.38|
Zynerba experiences a big setback for its experimental cannabinoid drug. That could be great news for GW Pharmaceuticals.
This clinical-stage cannabinoid-based drug developer has a long way to go to prove its worth to investors.
Despite big gains, these pot stocks appear to be headed in diverging directions.